Henry Meds vs Mochi vs Ro vs Form Health: GLP-1 Telehealth Compared (2026)
After the FDA removed semaglutide and tirzepatide from the shortage list in 2024 to 2025, the GLP-1 telehealth landscape consolidated around four major operators: Henry Meds, Mochi Health, Ro Body, and Form Health. Each took a different strategic position on the compounded vs brand-name question, the provider-led vs commodity question, and the price question. This guide explains the practical differences a patient comparing these four clinics should care about in 2026.
- › Henry Meds, Mochi, Ro Body, and Form Health are the four largest GLP-1 telehealth clinics in 2026.
- › Cheapest legitimate path: Ro Body + LillyDirect Zepbound vials at ~$494/month total.
- › Form Health is the premium option with ABOM-certified obesity medicine specialists at $544-$834/month.
- › Ro Body has the strongest insurance navigation team and highest brand-name PA approval rates.
- › Compounded pathway largely closed post-shortage delisting; sub-$300/month operators carry meaningful legal/clinical risk.
The Four Clinics at a Glance
Henry Meds: Subscription telehealth with provider visit included. Historically compounded semaglutide focused. After the shortage delisting, transitioned to brand-name Wegovy and Zepbound with insurance navigation as primary path. Cash-pay compounded remains available under personalized prescription exception rules.
Mochi Health: Female-founded telehealth focused on perimenopause-aware GLP-1 prescribing. Provider-led model with extended monitoring. Mix of brand and compounded depending on clinical fit.
Ro Body (formerly Roman, Sequence brand): Largest scale telehealth GLP-1 operator. Pivoted hard to brand-name post-shortage. Pioneered the LillyDirect partnership pathway. Strong insurance navigation. Provider model is more standardized.
Form Health: Premium model emphasizing obesity medicine specialist providers (board-certified ABOM physicians). Higher monthly cost but deeper clinical care, more comprehensive than the commodity GLP-1 telehealth competitors.
Cost Comparison 2026
Monthly all-in cost as of Q1 2026:
- Henry Meds: $297/month for the basic compounded protocol (where still legally available), or $99 to $199/month service fee + brand medication cost separately when prescribing Wegovy or Zepbound. Total range $99 to $850/month depending on path. - Mochi Health: $79 to $99/month membership fee, plus medication cost. Total approximately $200 to $700/month depending on brand vs compounded path. - Ro Body: $145/month for the membership and clinical care, plus medication. With LillyDirect Zepbound vials, total runs $494 to $694/month. With brand Wegovy plus savings card, total runs $644/month. - Form Health: $99 to $135/month service fee, plus medication. Total $544 to $834/month with brand-name. Higher fee reflects ABOM-certified specialist provider time.
The cheapest legitimate path in 2026 for cash-pay patients without insurance: Ro Body + LillyDirect Zepbound vials at ~$494/month. Mochi's compounded option may be cheaper when their personalized prescription pathway applies.
Provider Model and Care Quality
Provider model varies meaningfully across the four clinics:
Henry Meds employs nurse practitioners and physicians via async telehealth with structured intake. Provider time per patient is shorter on the basic tier. Upgraded plans include video visits.
Mochi Health uses provider-led model with longer initial intake and ongoing video check-ins. Clinical depth is above the commodity GLP-1 model. Specializes in metabolic and hormonal context.
Ro Body employs salaried providers (mix of physicians and NPs) with standardized protocols. High patient volume per provider. Care quality is consistent but less personalized than premium options.
Form Health employs board-certified obesity medicine specialists (ABOM diplomates) and dietitians. Provider time per patient is the longest of the four. Most appropriate for patients with complex metabolic profiles or those who want serious clinical engagement beyond just medication.
Insurance Navigation
All four clinics now offer some form of insurance navigation, but capabilities vary:
Ro Body has the strongest insurance navigation team, with dedicated benefits coordinators who handle prior authorizations across major commercial plans. Highest success rate for getting Wegovy or Zepbound covered.
Form Health, given the specialist provider model, often has higher PA approval rates because the documentation supporting medical necessity is more thorough.
Mochi Health offers insurance navigation but with smaller team. Mixed reports on PA success rates.
Henry Meds historically optimized for cash-pay compounded and has weaker insurance navigation infrastructure, though this is improving in 2026.
Which Clinic Should You Choose?
Pick Ro Body if: you want the most established operator, strong insurance navigation, and access to LillyDirect Zepbound vials as the cheapest brand-name path.
Pick Form Health if: you have a complex metabolic profile (diabetes, PCOS, hormonal imbalance), want a board-certified obesity medicine specialist, and budget for $200+ monthly service fee is acceptable.
Pick Mochi Health if: you are a female patient especially in the perimenopausal age range (40-55) and want a provider model that integrates hormonal context. Also if you want shorter-form provider visits with a still-decent clinical approach.
Pick Henry Meds if: you specifically want to access the compounded pathway under personalized prescription exception rules (where legal), and you are price-sensitive but want some clinical oversight beyond the cheapest commodity options.
For most patients without complex metabolic conditions or hormone considerations, Ro Body is the default best choice in 2026 because of price, scale, insurance team, and Eli Lilly partnership access.
What About Cheaper Compounded Clinics?
Below the four major clinics, dozens of smaller compounded GLP-1 telehealth operators still advertise $199 to $299/month protocols. The legal foundation for these has eroded substantially since the shortage delisting. Most operate under personalized prescription exceptions, which are case-by-case 503A allowances and not designed for scale.
Risks of the cheapest tier: medications may be sourced from compounding pharmacies that have received FDA warning letters, dosing may not be carefully controlled, clinical oversight is minimal, and the legal status of any individual prescription is uncertain. Some operators have already been shut down by state pharmacy boards in 2025 to 2026.
For most patients, the $200/month savings over the legitimate major clinics is not worth the legal and clinical uncertainty. The major four offer enough price competition (Ro Body + LillyDirect at $494/month is comparable to brand-name retail with savings cards) that the compounded discount is no longer as dramatic as it was in 2023.
Frequently Asked Questions
Which GLP-1 telehealth is cheapest in 2026? +
Ro Body with LillyDirect Zepbound self-pay vials is the cheapest legitimate brand-name path at approximately $494 to $694/month all-in. Mochi Health and Henry Meds may offer cheaper compounded options under personalized prescription pathways, but legal availability is narrower than it was during the shortage period.
Is Henry Meds still legitimate after the shortage delisting? +
Yes, Henry Meds continues to operate legally through brand-name prescribing and personalized prescription compounded pathways. The business model has shifted away from broad compounded access to a mix of brand and case-by-case compounded. Cash compounded availability is narrower than during the 2022-2024 peak.
Which clinic has the best providers? +
Form Health employs ABOM (American Board of Obesity Medicine) certified specialists, which is the deepest clinical credentialing of the four major clinics. For patients with complex metabolic conditions, Form Health is the appropriate choice. For straightforward weight loss in otherwise healthy patients, the other three are clinically appropriate at lower cost.
Will my insurance cover any of these? +
Insurance coverage depends on your plan and your diagnosis. Ro Body has the strongest insurance navigation team and highest success rates getting brand-name GLP-1s (Wegovy, Zepbound) covered. All four clinics offer some insurance navigation. Approximately 30-40% of large employer plans cover GLP-1s for obesity in 2026.
Can I switch between clinics? +
Yes, switching is straightforward. Cancel one subscription, sign up for another. Some clinics will transfer medical records if requested. No clinical reason to stay with one clinic if another better fits your needs or budget.
What about Calibrate and Found? +
Calibrate and Found were major players in 2022-2024 but have downsized significantly post-shortage. Calibrate restructured in late 2024 and has a narrower footprint in 2026. Found has shifted toward a more education-focused model. Both still operate but at smaller scale than Ro Body or Henry Meds.
Are there cheaper compounded clinics still operating? +
Yes, dozens of smaller operators still advertise $199-$299/month compounded protocols. The legal foundation eroded after the FDA delisting. Some operate under personalized prescription exception rules; some operate in legal gray areas; some have already been shut down by state pharmacy boards. We do not recommend the cheapest tier unless you have specifically verified the operator and the source pharmacy.
Bottom Line
For most cash-pay patients in 2026 seeking the best combination of price, legitimacy, and clinical care, Ro Body is the default best choice because of pricing through LillyDirect, scale, and insurance navigation. Form Health is appropriate for patients with complex metabolic conditions willing to pay the premium for ABOM specialists. Mochi Health is appropriate for women in the perimenopausal age range. Henry Meds remains a legitimate option but the value proposition has narrowed since the shortage period.
Sources
- Provider websites (henrymeds.com, joinmochi.com, ro.co, formhealth.co), Q1 2026 pricing. (Current published pricing)
- FDA shortage list delisting announcements (October 2024 tirzepatide, February 2025 semaglutide). (Regulatory timeline)
- ABOM diplomate directory (abom.org). (Form Health provider credentialing)